

VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

Company



2023/02/03 22:00:00

Price
301.02
USD

Difference -0.91%(-2.76)



Contact Details

VERTEX PHARMACEUTICALS
INC.

--

50 Northern Avenue

02210 Boston

Tel: 1-617-341-6100

Fax: -

Web: <http://www.vrtx.com>

E-mail:
mediainfo@vrtx.com

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	9,560,600,000		8,133,379,000		4,822,829,000	
Common stock capital		2,500,000		2,599,000		2,589,000
Fixed assets	3,871,900,000		3,618,429,000		3,495,636,000	
Equity capital of a company		10,100,000,000		8,686,815,000		6,085,244,000
Cash and cash equivalents	6,800,100,000		5,988,845,000		3,117,326,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		2,142,000,000		1,877,533,000		1,334,827,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,190,500,000		1,187,460,000		898,394,000
Different income		-		-		-
Other liabilities		303,300,000		297,955,000		275,526,000
Total assets	13,432,500,000	13,432,500,000	11,751,808,000	11,751,808,000	8,318,465,000	8,318,465,000

Balance notes

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	3,900	3,400	3,000
Equity ratio	75.19%	73.92%	73.15%
Debt-equity ratio	33.00%	35.28%	36.70%

Others

	2021	2020	2019
Tax Expense Rate	14.22%	13.00%	15.64%

VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

Income statement

	2021	2020	2019
Turnover	7,604,400,000	6,209,397,000	4,130,275,000
Net income	2,342,100,000	2,711,647,000	1,176,810,000
EBIT	2,530,874,700	2,862,975,951	1,262,025,618
Operating income before taxes	2,730,400,000	3,116,798,000	1,394,919,000
Cash Flow	2,643,500,000	3,253,505,000	1,569,330,000
Net interest income	-56,600,000	-35,912,000	5,176,000
Research and development expenses	3,051,100,000	1,829,537,000	1,754,540,000
Income taxes	388,300,000	405,151,000	218,109,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,770,655	1,658,457	1,250,234

Board of Directors

Members of Management Board

Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Margaret McGlynn	Member of Board of Directors
Suketu Upadhyay	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Yuchun Lee	Member of Board of Directors
Reshma Kewalramani, M.D.	Chairman of Managing Board
David Altshuler	Member of Executive Committee
Jeffrey Leiden	Member of Executive Committee
Amit K. Sachdev	Member of Executive Committee
Bastiano Sanna, Ph.D.	Member of Executive Committee
Carmen Bozic, M.D.	Member of Executive Committee
Charles F. Wagner, Jr.	Member of Executive Committee
Damian Wimot	Member of Executive Committee
Joy Liu	Member of Executive Committee
Ludovic Fenoux	Member of Executive Committee
Mark Bunnage	Member of Executive Committee
Michael Partridge	Member of Executive Committee
Mike Tirozzi	Member of Executive Committee
Nia Tatsis, Ph.D.	Member of Executive Committee
Nina Devlin	Member of Executive Committee